Paladin wins FDA OK for tropical disease drug; Emmaus touts PhIII success for sickle cell drug;

@FierceBiotech: Biotechs bag $170M in IPO cash as a booming quarter winds down. Article | Follow @FierceBiotech

@JohnCFierce: Sanofi launches a vaccine R&D program with blockbuster Prevnar 13 in its sights. News | Follow @JohnCFierce

@DamianFierce: Liver risks put another Geron trial on ice, but the damage has largely been done already. More | Follow @DamianFierce

@EmilyMFierce: Survey: 1 in 5 Americans think doctors know vaccines cause autism. Story via FierceVaccines | Follow @EmilyMFierce

> Canada's Paladin Labs has won FDA approval for Impavido to treat the tropical disease leishmaniasis. Impavido is the first FDA-approved drug to treat cutaneous or mucosal leishmaniasis. "Today's approval demonstrates the FDA's commitment to making available therapeutic options to treat tropical diseases," said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research. Release

> Torrance, CA-based Emmaus Life Sciences reports that the company has wrapped a successful Phase III study for sickle cell anemia. Investigators say they mapped a 25% reduction in sickle cell crises and a 33% drop in hospitalizations for patients taking their therapy. According to the company's 10-K. Emmaus has been testing L-glutamine in the trial. L-glutamine is an amino acid found in skeletal muscle which is currently sold as a nutritional supplement. Release

> Richmond, CA-based Sangamo ($SGMO) is raising $100 million through a stock offering. Release

Medical Device News

@FierceMedDev: Corning leads NinePoint's new $34M Series B--a big round for the next-gen imaging tech developer. More | Follow @FierceMedDev

@MarkHFierce: This is the kind of pacer I'd like to try. Wild stuff. Feature via PopSci | Follow @MarkHFierce

@MichaelGFierce: Drug delivery in space? NASA contributes to the field with microcapsules developed by ISS Research. More via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Congress wants more answers from the FDA about its regulation of mobile medical apps. Story | Follow @EmilyWFierce

> St. Jude Medical nails CE mark for 'burst' neurostim treatment of chronic pain. More

> Bacterin 2013 revenues improve slightly; net losses rise significantly. Story

Pharma News

@FiercePharma: Pay-for-delay: Is cash the only antitrust test that matters in patent settlements? Story | Follow @FiercePharma

@TracyStaton: Should gastro specialist Salix snap up Furiex and its IBS drug candidate? More | Follow @TracyStaton

@EricPFierce: Even an OTC drugmaker can have research published in New England Journal of Medicine. News | Follow @EricPFierce

@CarlyHFierce: Valeant's CEO, a crackerjack cost-cutter, seeks more 'fat' companies to buy. Piece | Follow @CarlyHFierce

> J&J blazes a new pharma trail with industry's first designer-in-chief. Article

> AstraZeneca unveils direct-to-patient Nexium sales to fend off generic rivals. More

Pharma Manufacturing News

> Novartis CEO predicts generic industry fallout as quality takes center stage. Story

> FDA jumps compounder for making unapproved domperidone. News

> FDA cuts U.S. plant inspections while boosting them overseas. Story

> Indian regulator finds number of substandard drugs on the rise. Article

> Parexel opens Singapore distribution facility. Story

> OTC maker has discovery published in New England Journal of Medicine. Brief

Vaccines News

> Novartis to submit Bexsero to FDA in Q2. News

> 1 in 5 Americans think doctors know vaccines cause autism. Survey

> Amgen posts positive PhIII data as judgment day for cancer vaccine bet nears. News

> Failure of sexual health clinics to offer HPV vaccine leaves high-risk groups vulnerable. Story

> Circassia begins trading in London following successful IPO. News

> Sanofi inks a Korean alliance to develop a pneumococcal vaccine. Brief

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.